1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Oxygenta Pharmaceutical Ltd.

Oxygenta Pharmaceutical Ltd.

OXYGENTAPH.BO
Oxygenta Pharmaceutical Ltd.IN flagBombay Stock Exchange
46.60
INR
-0.40
- -
1.72BMarket Cap
Oxygenta Pharmaceutical Ltd.
OXYGENTAPH.BO
(Bombay Stock Exchange)

Recent

price

46.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
- -
- -
2.42
6.12
12.18
7.99
12.62
20.1
13.44
51
47.49
21.82
12.37
30.35
- -
30.41
Revenue per Share
-0.23
-1.64
-4.2
-5.99
-5.39
-5.69
-4.44
-3.19
-5.67
2.87
-0.48
-8.15
-1.09
-2.86
- -
-4.73
Basic EPS, GAAP
-0.19
-0.6
-2.64
-4.2
0.83
0.51
1.26
-7.64
-3.05
-8.2
-5.2
-7.94
-5.35
-2.38
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-3.25
-4.89
-9.09
-15.75
-21.14
-26.84
-31.28
-34.47
-40.11
-37.27
-27.17
-32.53
-9.49
-10.16
- -
9.95
Book Value per Share
-3.25
-4.89
-9.09
-15.75
-21.14
-26.84
-31.28
-34.47
-40.11
-37.27
-27.17
-32.53
-6.28
-6.95
- -
-11.49
Tangible Book Value per Share
10
10
10
10
10
10
10
10
10
10
13
14
32
36
- -
37
Basic Weighted Avg Shares
- -
- -
25
62
124
82
129
205
137
520
605
310
396
1,093
1,130
1,130
Sales/Revenue/Turnover
- -
- -
-175.02
-106.68
-40.15
-70.44
-38.37
-14.93
-64.64
5.09
-0.19
-29.52
-31.14
-12.53
-15.66
-15.66
Operating Margin (%)
- -
- -
9
25
8
9
9
10
10
12
16
21
27
36
23
23
Depreciation Expense
-2
-17
-43
-61
-55
-58
-45
-33
-58
29
-6
-116
-35
-103
-176
-176
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.81
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-173.61
-97.96
-44.26
-71.24
-35.18
-15.87
-42.2
5.63
-1.01
-37.34
-8.78
-9.42
-15.55
-15.56
Profit Margin (%)
-88
-93
-105
-103
-66
-114
-154
-92
-102
-16
15
-79
-96
-549
-347
-347
Working Capital
43
81
106
143
171
185
180
209
254
450
510
623
490
215
753
753
LT Debt
-33
-50
-93
-161
-216
-274
-319
-352
-409
-380
-346
-462
-201
-250
-427
-427
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
-290.69
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-220.24
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-47.24
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
458
- -
343
LT Borrowings
271
- -
753
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
- -
37
Market Capitalization
2,493
2,045
1,798

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
519
- -
514
Cash, Cash Equivalents & STI
12
- -
21
Accounts Receivable, Net
157
- -
100
Inventories
271
- -
294
Total Current Liabilities
1,250
- -
861
Payables & Accruals
- -
- -
- -
ST Debt
458
- -
343
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.6%
12.6%
70.58%
Free Cash Flow
-6.5%
85.17%
374.39%
Net Income, GAAP
175.4%
374.26%
70.63%
Sales/Revenue/Turnover
50.35%
34.91%
3.37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
69
131
91
106
396
2025
126
140
332
495
1,093
2026
151
143
339
496
1,130

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.65
-0.87
-1.12
- -
-1.09
2025
-0.39
-0.81
-1.07
-0.6
-2.86
2026
-1.65
-1.33
-1.32
-0.45
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
NIHON CHOUZAI Co.,Ltd. (3341.T)
PharmaResearch Co., Ltd. (214450.KQ)
Kissei Pharmaceutical Co., Ltd. (KSPHF)
China BCT Pharmacy Group, Inc. (CNBI)
InNexus Biotechnology, Inc. (IXSBF)
Neighbourly Pharmacy Inc. (NBLY.TO)
Business
Oxygenta Pharmaceutical Ltd is an Indian pharmaceutical company specializing in the manufacture and sale of bulk drugs, active pharmaceutical ingredients (APIs), and pharmaceutical preparations including medical and veterinary products. Its main product portfolio encompasses antihypertensive drugs, anticancer drugs, antiulcer drugs, antiretroviral drugs, antiviral drugs, and intermediates such as losartan potassium and gabapentin. The company provides regulatory services, containment solutions, and supplies a range of APIs and excipients, positioning itself as a key player within the pharmaceutical supply chain. Founded in 2011 and headquartered in Telangana, India, Oxygenta operates primarily within the Indian pharmaceutical market. In recent strategic developments, Oxygenta Pharmaceutical underwent significant management changes in 2025 including the resignation of its managing director and other key officers. The company also experienced a promoter shareholding reclassification and attracted investment interest with a notable acquisition of a 28.7% stake by M V S Prasad Reddy in April 2024. Operationally, Oxygenta has continued to expand its manufacturing capabilities and diversified its product range to address complex therapies, with a focus on oncology and chronic disease medications. These changes reflect ongoing efforts to strengthen its market position and expand its operational footprint in India. The company remains listed on the Bombay Stock Exchange, reinforcing its commitment to transparency and market engagement.